Atenolol kinetics in renal failure

Area of Science:

• Pharmacokinetics
• Nephrology
• Cardiology

Background:

• Atenolol is a beta-blocker commonly prescribed for cardiovascular conditions.
• Renal function significantly influences drug elimination.
• Understanding atenolol's pharmacokinetics in renal impairment is crucial for safe and effective dosing.

Purpose of the Study:

• To investigate the impact of varying degrees of renal function on atenolol blood and urine levels.
• To determine the relationship between creatinine clearance and atenolol's pharmacokinetic parameters.
• To establish dosing guidelines for atenolol in patients with renal failure.

Main Methods:

• Single-dose and repeated-dose pharmacokinetic studies involving 12 subjects with diverse renal function.
• Measurement of atenolol blood and urine concentrations over time.
• Correlation analysis between pharmacokinetic parameters and renal function markers (creatinine clearance, serum creatinine).

Main Results:

• Atenolol's peak blood levels occurred later, and 24-hour plasma concentrations increased as creatinine clearance decreased.
• Blood atenolol half-life (t1/2) extended from approximately 6 hours to over 100 hours with progressive renal failure.
• Elimination rate constant decreased, and area under the curve increased with reduced renal function.

Conclusions:

• Renal function is a critical determinant of atenolol's pharmacokinetic profile.
• Significant accumulation of atenolol can occur in patients with impaired kidney function.
• Adjusted dosing strategies are necessary for patients with renal failure to optimize atenolol therapy.